Hengrui Yuanzheng (Shanghai) Biotechnology
Developing precision medicines and immunotherapies for solid tumors
About Hengrui Yuanzheng (Shanghai) Biotechnology
Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd. is a biopharmaceutical company founded in 2015, specializing in the development of precision medicines and immunotherapy products for solid tumors. The company was established as a joint venture between Jiangsu Hengrui Pharmaceuticals Group and Shenzhen Yuanzheng Cell. The company is headquartered in Shanghai, with wholly-owned subsidiaries and cell therapy research centers in Shenzhen and Guangzhou.
The company's core technology is the Multiple Antigen Specific Cell Therapy (MASCT), described as a fourth-generation tumor autologous immune cell therapy technique. Their primary product, the multi-antigen autologous immune cell injection (MASCT-I), has received approval for clinical trials from the National Medical Products Administration of China and is currently in Phase II trials for treating advanced soft tissue sarcoma. Hengrui Yuanzheng's product pipeline also includes TCR-T immune cell products and TCR bispecific antibody products. The company focuses on developing treatments for a variety of cancers, including melanoma, non-small cell lung cancer, breast cancer, colorectal cancer, and soft tissue sarcomas.
Hengrui Yuanzheng has secured multiple rounds of funding, including a Series A, and subsequent B, C, and C++ rounds with investments from firms like Green Pine Capital Partners, Sincere VC, and CICC Capital. The company has a team of nearly 100 professionals dedicated to the research, development, and production of its innovative drugs. The chairman of the parent company, Hengrui Pharma, is Sun Piaoyang. The legal representative of Hengrui Yuanzheng is Li Kejian.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jan 2024 | $14M | $138M | China Science and Technology Innovation · Goldport Capital | ↗ |
| SERIES C✓Equity / VC | May 2023 | $28M | $110M | China Science and Technology Innovation · Hengrui Pharma · Goldport Capital | ↗ |
Growth signals
Latest recorded traffic for Hengrui Yuanzheng (Shanghai) Biotechnology is 700 monthly website visits, up 1650% over the last three months. Hengrui Yuanzheng (Shanghai) Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hengrui Yuanzheng (Shanghai) Biotechnology in its local ecosystem
The Hengrui Yuanzheng (Shanghai) Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
- CIChina Science and Technology Innovation
Hengrui Pharma
Goldport Capital
Other known investors1 additional known investor
Shanghai Jiao Tong University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hengrui Yuanzheng (Shanghai) Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hengrui Yuanzheng (Shanghai) Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








